SCHEMBL3352141

SCHEMBL3352141

Cc1nc2ccccn2c1-c1nc(C2(c3cccc(C(=O)NO)c3)CC2)sc1C

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AKT1 P31749 1/20 0.39
AKT2 P31751 1/20 0.39
LMNA P02545 2/20 0.38
CACNA1B Q00975 1/20 0.37
APBA1 Q02410 1/20 0.37
KLF5 Q13887 1/20 0.37
GAA P10253 3/20 0.37
SMN1; SMN2 Q16637 2/20 0.37
RAB9A P51151 2/20 0.37
KDM4E B2RXH2 3/20 0.37
ALDH1A1 P00352 2/20 0.37
NPSR1 Q6W5P4 2/20 0.37
MAPT P10636 1/20 0.37
NR2F2 P24468 1/20 0.37
HTT P42858 1/20 0.37
KMT2A Q03164 1/20 0.37
ROCK2 O75116 1/20 0.36
NPC1 O15118 1/20 0.36
TP53 P04637 1/20 0.36
CDK4 P11802 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3348291 0.91 AKT1 (0.38) AKT1AKT2LMNAGAAKDM4E
SCHEMBL3352579 0.88 HDAC1 (0.49) LMNACDK4CCNE1CDK2HDAC1
SCHEMBL3350719 0.88 AKT1 (0.39) AKT1AKT2LMNAGAAKDM4E
SCHEMBL197516 0.85 GAA (0.39) AKT1AKT2GAASMN1; SMN2RAB9A
SCHEMBL3353327 0.85 MARK3 (0.39) GAASMN1; SMN2RAB9AHTTNPC1
SCHEMBL3355176 0.85 GAA (0.48) LMNACACNA1BAPBA1KLF5GAA
SCHEMBL3357662 0.80 CDK2 (0.50) KDM4EALDH1A1CDK4CCNE1CDK2
SCHEMBL3353718 0.79 HDAC1 (0.52) CDK4CCNE1CDK2HDAC1
SCHEMBL3352620 0.76 HDAC1 (0.51) CDK4CCNE1CDK2HDAC1
SCHEMBL3354200 0.76 PIK3CA (0.40) SMN1; SMN2RAB9AKDM4EALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8198299-B2 Cycloalkylidene and heterocycloalkylidene inhibitor compounds GILEAD SCIENCES, INC. (US) 2012-06-12 US claimed
US-20100022543-A1 CYCLOALKYLIDENE AND HETEROCYCLOALKYLIDENE INHIBITOR COMPOUNDS GILEAD SCIENCES, INC. 2010-01-28 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100022543-A1 CYCLOALKYLIDENE AND HETEROCYCLOALKYLIDENE INHIBITOR COMPOUNDS HDAC1, HDAC11, HDAC2 AKT1 1338/4885AKT2 981/4885LMNA 1594/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.